Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Palisade Bio Inc PALI

Healthcare Biotechnology
Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD... see more

Recent & Breaking News (NDAQ:PALI)

Neuralstem to Participate at the BIO 2018 International Convention

GlobeNewswire May 29, 2018

Neuralstem Provides Business Update and Reports First Quarter 2018 Fiscal Results

GlobeNewswire May 15, 2018

Neuralstem Announces Publication of Long-Term Follow-up Data on ALS in the Annals of Clinical and Translational Neurology

GlobeNewswire May 3, 2018

Neuralstem to Present Clinical Update at the Alliance for Regenerative Medicine 6th Annual Cell & Gene Therapy Investor Day

GlobeNewswire April 11, 2018

36 Biggest Movers From Yesterday

Benzinga.com  April 11, 2018

25 Stocks Moving In Tuesday's Mid-Day Session

Benzinga.com  April 10, 2018

Benzinga Pro's 5 Stocks To Watch Today

Benzinga.com  April 10, 2018

25 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  April 10, 2018

Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic Spinal Cord Injury

GlobeNewswire April 10, 2018

Neuralstem Reports Year End 2017 Fiscal Results and Business Update

GlobeNewswire April 2, 2018

Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury 

GlobeNewswire March 13, 2018

Neuralstem to Participate at Upcoming Investor Conferences

GlobeNewswire March 12, 2018

Neuralstem to Participate at The Young Jewish Professionals CEO Healthcare Symposium

GlobeNewswire February 8, 2018

Neuralstem to Participate at Cell and Gene Therapy World

GlobeNewswire January 22, 2018

Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology

GlobeNewswire January 5, 2018

New Member appointed to the Board of Directors of Neuralstem

GlobeNewswire December 20, 2017

30 Stocks Moving In Wednesday's Mid-Day Session

Benzinga.com  December 6, 2017

28 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  December 6, 2017

Neuralstem Presents Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive Disorder at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting

GlobeNewswire December 5, 2017

Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting

GlobeNewswire November 16, 2017